Neurvati Neurosciences
PrivateLast Round
Series D
May 27, 2025
Total Funding Raised
$140M
Momentum Score
50 /100
Company Overview
Neurvati Neurosciences is a clinical-stage biotechnology company established in September 2021 as a portfolio company of Blackstone Life Sciences. The company operates on a "search-evaluate-invest-develop" model to identify, acquire, and advance a portfolio of therapies for a broad range of neurological and psychiatric disorders. Neurvati's strategy involves advancing late-stage, de-risked assets and establishing fit-for-purpose subsidiary companies, such as GRIN Therapeutics, to develop specific programs. The company aims to accelerate treatment options by leveraging its team's expertise in all phases of drug development and commercialization, supported by the resources of Blackstone.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Biotechnology, Mental Health
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Neurvati Neurosciences Comps
Public and private peers based on sector, stage, and business model.
Neurvati Neurosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | May 27, 2025 |
Neurvati Neurosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Blackstone Life Sciences | Series D |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 13, 2025
Carlos Martin appointed as the new Chief Commercial Officer.
- Jun 18, 2025
Gail M. Farfel joins the board of directors.
Neurvati Neurosciences Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Neurvati Neurosciences's valuation, stock price, and market status.
